High Blood Pressure Drugs Market Scope
Hypertension is described as a persistent increase in blood pressure outside the normal limit. Hypertension is characterized as a systolic/diastolic pressure that is consistently greater than 140/90mmHg, according to the World Health Organization. Antihypertensives are a form of blood pressure medication (high blood pressure). Alternative treatments for people with hypertension include angiotensin conversion enzyme inhibitors (ACEIs), calcium channel blockers (CCBs), angiotensin-receptor blockers (ARBs), beta-blockers, and diuretics. Thiazide diuretics are the most known first-line antihypertensives in reducing morbidity and mortality among most patients with hypertension. However, antihypertensives have side effects, the most frequent of which include a constant dry cough, dizziness, taste disturbances, swollen knees, constipation, and rashes. The market for antihypertensives is observed to grow at increasing rate owing to multiple factors including the prevalence of Hypertension and emergence of advance therapeutic techniques.
The High Blood Pressure Drugs market study is segmented by Type (Diuretics, Angiotensin Converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (ARBs), Beta Blockers, Vasodilators, Alpha Blockers, Renin Inhibitors and Others), by Application (Hospital Pharmacy, Retail Pharmacy and Online Pharmacy) and major geographies with country level break-up.
The global market is highly competitive and consists of a limited number of providers who compete with each other. The intense competition, changing consumer spending patterns, demographic trends, and frequent changes in consumer preferences pose significant opportunities for market growth. Research Analyst at AMA estimates that United States & German Players will contribute to the maximum growth of Global High Blood Pressure Drugs market throughout the predicted period.
Pfizer Inc. (Uinted States), Novartis AG (Switzerland), Sanofi (France), Merck & Co., Inc. (Germany), Johnson & Johnson Services, Inc. (United States), AstraZeneca (United Kingdom), Daiichi Sankyo Company, Limited. (Japan) and Ranbaxy Laboratories (Sun Pharma) (India) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Boehringer Ingelheim International GmbH (Germany), Lupin (India), Actavis (United States) and Roche Holding AG (Switzerland).
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.
AMA Research has segmented the market of Global High Blood Pressure Drugs market by Type, Application and Region.
On the basis of geography, the market of High Blood Pressure Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
United States, Food and Drug Administration, “E12A Principles for Clinical Evaluation of New Antihypertensive Drugs” - Lays Out General Guidelines for Evaluating Novel Antihypertensive Drugs in Clinical Trials and Provides Core Criteria for Evaluating Antihypertensives That Are Agreed in All Three ICH Countries, But There Are Some Regional Variations. and European Society of cardiology, “2018 ESC/ESH Clinical Practice Guidelines for the Management of Arterial Hypertension” – Provides Standards for Classification, Administration and Dosage limitations for Anti-Hypertensive Drugs for the Management of Arterial Hypertension, Across the European Union.
- Technical Progress in Healthcare Sector
- Prevalence of Hypertension
- Demand for Non-pharmacological Therapy
- Rising Healthcare Awareness
- Heavy Investments in Healthcare Research & Development
- Unexplored Markets
- Side Effects and Adverse Reactions
Key Target AudienceAnti-Hypertensive Drug Manufactures, New Entrants and Investors, Anti-Hypertensive Drug Distributors and Suppliers, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others
Frequently Asked Questions (FAQ):
1. Is it possible to have certain customization in the study?
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a study that suits your business objectives.
2. How big is the High Blood Pressure Drugs Market?
Yes, the study does represent market size by key business segment, application/end users and major geographies forecasted till 2026.